Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00622193 · ClinicalTrials.gov registry record · Phase 2
Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer
A Phase 2 study, sponsored by Helsinn Therapeutics (U.S.).
- Completed
- Registry status
- Phase 2
- Development phase
- 228
- Enrollment target
NCT00622193: Completed Phase 2 study, sponsored by Helsinn Therapeutics (U.S.).
NCT00622193 is a Phase 2 study that has completed, run by Helsinn Therapeutics (U.S.). The registered enrollment target is 228 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00622193, a Phase 2 study, has completed, sponsored by Helsinn Therapeutics (U.S.).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 228 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate doses of anamorelin for safety and efficacy in patients with non-small cell lung cancer.
Interventions
- DRUG placebo
- DRUG anamorelin HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2008-03 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
What the finished NCT00622193 record still lists
NCT00622193 is an interventional study that assigns participants to a tested intervention. The registered 228 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% higher).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00622193 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00622193 about?
NCT00622193 is a clinical study titled "Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer". The purpose of this study is to evaluate doses of anamorelin for safety and efficacy in patients with non-small cell lung cancer.
What is the current status of trial NCT00622193?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 228 participants. The study started on 2008-03. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00622193?
The interventions under investigation include: placebo (DRUG), anamorelin HCl (DRUG).
Who is sponsoring clinical trial NCT00622193?
This trial is sponsored by Helsinn Therapeutics (U.S.), which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00622193's enrollment target sits among peer trials
228 264th of 2000 higher than 1,736 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05107908 · 228 participants · NA
Neuronal and Behavioral Effects of an Implicit Priming Approach to Improve Eating Behaviors in Obesity
- NCT05547698 · 228 participants · NA
A Study of Venoarterial ECMO vs Off-Pump Bilateral Orthotopic Lung Transplantation
- NCT05630963 · 228 participants
Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression
- NCT06073665 · 228 participants · Phase 4
Dosing of LT4 in Older Individuals
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia